

Ref. No: FO11130
Date: 09/08/2024
Subject: Asthma medication

REQUEST

Could you please answer the questions below:

Q1 - How many patients have been treated (for any condition) in the last 4 months with:

**Benralizumab
Dupilumab
Omalizumab
Reslizumab
Mepolizumab
Tezepelumab**

Q2 - Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

**Age 6-11
Age 12-17
Age 18 and above**

Q3 - How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

**Dupilumab
Omalizumab**

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

Q1. How many patients have been treated (for any condition) in the last 4 months with:

Southport and Ormskirk response.

- **Benralizumab - 0**
- **Dupilumab - <5**
- **Omalizumab - 7**
- **Reslizumab - 0**
- **Mepolizumab - 0**
- **Tezepelumab – 0**

STHK response

- **Benralizumab - 0**
- **Dupilumab - 98**
- **Omalizumab - 24**
- **Reslizumab - 0**
- **Mepolizumab - 0**
- **Tezepelumab – 0**

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

Southport and Ormskirk response

- **Age 6-11 - 0**
- **Age 12-17 - 0**
- **Age 18 and above - 11**

STHK response

- **Age 6-11 - 0**
- **Age 12-17 - <5**
- **Age 18 and above - 118**

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

Southport and Ormskirk response

- **Dupilumab** - 0
- **Omalizumab** - 6

STHK response:

- **Dupilumab** - 0
- **Omalizumab** - 0

*<5

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.